Lipton Injection is NOT a Recognized Treatment for Prostate Cancer
There is no medical treatment called "Lipton injection" for prostate cancer in any established clinical guidelines or medical literature. This appears to be either a misunderstanding or miscommunication about the treatment name.
Standard Treatment Options for Gleason 7 Prostate Cancer
For a man with newly diagnosed localized Gleason 7 prostate cancer, the established treatment options depend on whether the disease is classified as favorable or unfavorable intermediate-risk and the patient's life expectancy.
Risk Stratification for Gleason 7 Disease
Favorable intermediate-risk Gleason 3+4=7 disease is defined when ALL of the following are present: 1
- Primary Gleason pattern 3 (not 4+3)
- Less than 50% of biopsy cores contain cancer
- Only ONE intermediate-risk factor (PSA 10-20 ng/mL OR clinical stage T2b-c, but not both)
Unfavorable intermediate-risk is identified by ANY of the following: 1
- 50% or more cores positive
- Multiple intermediate-risk factors
- Primary Gleason pattern 4 (i.e., Gleason 4+3=7)
Treatment Recommendations Based on Life Expectancy
For Life Expectancy Less Than 10 Years:
- Observation or active surveillance is appropriate, as definitive therapy often causes more harm than benefit given competing health risks 1, 2
- Alternative options include radiation therapy with or without 4-6 months of androgen-deprivation therapy (ADT), or brachytherapy alone 3
For Life Expectancy 10 Years or Greater with Favorable Intermediate-Risk:
Active surveillance is now an acceptable option when patients are fully informed and agree to close monitoring with regular PSA testing and repeat biopsies 1
Definitive treatment options include: 4, 5, 1
- Radical prostatectomy with pelvic lymph node dissection (when estimated nodal involvement risk ≥2%)
- External-beam radiation therapy (EBRT) combined with 4-6 months of ADT
- Brachytherapy alone or combined with EBRT
The 5-year biochemical-recurrence-free survival after radical prostatectomy for favorable intermediate-risk patients is approximately 88% 1
For Life Expectancy 10 Years or Greater with Unfavorable Intermediate-Risk:
Definitive treatment is strongly recommended; active surveillance is NOT appropriate 1, 2
The same definitive modalities apply (radical prostatectomy, EBRT with ADT, or brachytherapy), but observation is excluded 1
Important Distinctions in Gleason 7 Disease
The distinction between Gleason 3+4=7 and 4+3=7 is critical, as the predominant pattern 4 in 4+3=7 confers significantly worse prognosis 1, 6. Patients with Gleason 7 disease should not be grouped with Gleason 5-6 patients, as they have worse outcomes and may benefit from more aggressive treatment strategies 6
Common Pitfall to Avoid
Do not use androgen-deprivation therapy (ADT) alone as primary treatment for localized prostate cancer, as it does not improve survival 2. ADT should only be used in combination with radiation therapy for intermediate- to high-risk disease 4, 3
Next Steps
If you are asking about a specific treatment that sounds like "Lipton," please clarify the exact name with your healthcare provider. Possible alternatives that might be confused include:
- Lupron (leuprolide) - a form of ADT/hormone therapy
- Lutetium (Lu-177-PSMA) - used for metastatic disease, not localized cancer
The appropriate treatment should be selected based on the specific Gleason pattern (3+4 vs 4+3), PSA level, clinical stage, percentage of positive cores, patient age, life expectancy, and patient preferences after thorough shared decision-making 5, 1